EWS-FLI1 and Activator Protein-1 (AP-1) Reciprocally Regulate Extracellular-Matrix Proteins in Ewing sarcoma Cells

Area of Science:

• Oncology
• Molecular Biology
• Cancer Genetics

Background:

• Ribonucleotide reductase (RNR) is a key enzyme in DNA synthesis and a target for chemotherapy drugs like gemcitabine.
• RNR inhibition in Ewing sarcoma previously showed altered expression of transcription factors, including activator protein-1 (AP-1) and c-Myc.
• The specific roles and targets of AP-1 in Ewing sarcoma remain largely uncharacterized.

Purpose of the Study:

• To investigate the functional roles and downstream targets of AP-1 in Ewing sarcoma.
• To elucidate the interplay between AP-1 and EWS-FLI1 in regulating gene expression and cellular phenotype in Ewing sarcoma.
• To identify novel molecular mechanisms driving Ewing sarcoma progression.

Main Methods:

• Utilized genetically defined models of Ewing sarcoma.
• Performed transcriptome profiling to analyze gene expression changes.
• Employed gene-set enrichment analysis to identify regulated pathways and functions.

Main Results:

• Identified reciprocal regulation between AP-1 and EWS-FLI1 concerning extracellular matrix proteins (fibronectins, integrins, collagens).
• Demonstrated that AP-1 expression influences Ewing sarcoma cell morphology and phenotype.
• Confirmed EWS-FLI1 dysregulates AP-1 protein expression, supporting known interactions.

Conclusions:

• Ewing sarcoma exhibits unique features driven by EWS-FLI1, including reciprocal regulation of extracellular matrix components by AP-1 and EWS-FLI1.
• This study reveals a novel regulatory axis impacting Ewing sarcoma biology.
• Findings provide new insights into the molecular underpinnings of Ewing sarcoma and potential therapeutic targets.